KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Accounts Payables (2016 - 2025)

BeOne Medicines (ONC) has disclosed Accounts Payables for 11 consecutive years, with $479.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 18.28% to $479.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $479.0 million, a 18.28% increase, with the full-year FY2025 number at $479.0 million, up 18.28% from a year prior.
  • Accounts Payables was $479.0 million for Q4 2025 at BeOne Medicines, up from $383.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $479.0 million in Q4 2025 to a low of $146.9 million in Q1 2021.
  • A 5-year average of $297.9 million and a median of $301.2 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: soared 61.25% in 2022, then dropped 10.04% in 2024.
  • BeOne Medicines' Accounts Payables stood at $262.4 million in 2021, then rose by 12.34% to $294.8 million in 2022, then rose by 6.9% to $315.1 million in 2023, then increased by 28.53% to $405.0 million in 2024, then rose by 18.28% to $479.0 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Accounts Payables are $479.0 million (Q4 2025), $383.7 million (Q3 2025), and $360.8 million (Q2 2025).